Clinical Trials

NCT Number: NCT04983862 Phase: PHASE1 Trial Summary: This study will test the safety of using Illuminare-1 during standard surgery for prostate cancer. The study researchers will test increasing doses of Illuminare-1 to find the dose – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

NCT Number: NCT04947254 Phase: Phase 2 Trial Summary: This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer tha – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center Acronym:

NCT Number: NCT04981834 Phase: Not Applicable Trial Summary: This phase III trial compares the effects of robot-assisted radical prostatectomy (RARP) with or without vesicopexy on urinary continence (a person’s ability to control their bladd – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Southern California|National Cancer Institute (NCI) Acronym:

NCT Number: NCT04945642 Phase: Not Applicable Trial Summary: This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, als – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Jonsson Comprehensive Cancer Center Acronym: HYDRA

NCT Number: NCT04905069 Phase: Not Applicable Trial Summary: To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat pr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Boston Scientific Corporation Acronym: SABRE

NCT Number: NCT04925284 Phase: Phase 1 Trial Summary: This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Exelixis Acronym:

NCT Number: NCT04915508 Phase: Phase 2 Trial Summary: This phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has risi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Jonsson Comprehensive Cancer Center Acronym: EXCALIBUR

NCT Number: NCT04898634 Phase: Phase 1 Trial Summary: The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion) – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Janssen Research & Development, LLC […]

NCT Number: NCT04868604 Phase: Phase 1|Phase 2 Trial Summary: The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant p – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Clarity Pharmaceuticals Ltd Acronym: SECuRE

NCT Number: NCT04890613 Phase: Phase 1 Trial Summary: This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients w – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Senhwa Biosciences, Inc. Acronym: